CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate

被引:20
作者
Bocchia, M. [1 ]
Ippoliti, M. [1 ]
Gozzetti, A. [1 ]
Abruzzese, E. [2 ]
Calabrese, S. [1 ]
Amabile, M. [3 ]
Pirrotta, M. T. [1 ]
Crupi, R. [1 ]
Tozzuoli, D. [1 ]
Trawinska, M. M. [2 ]
Defina, M. [1 ]
Martinelli, G. [3 ]
Lauria, F. [1 ]
机构
[1] Univ Siena, Dept Hematol, I-53100 Siena, Italy
[2] Univ Roma Tor Vergata, Dept Hematol, Rome, Italy
[3] Univ Bologna, Hematol & Clin Oncol Seragnoli Inst, Bologna, Italy
关键词
D O I
10.1038/sj.leu.2404893
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:426 / 428
页数:4
相关论文
共 8 条
[1]   Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment [J].
Bhatia, R ;
Holtz, M ;
Niu, N ;
Gray, R ;
Snyder, DS ;
Sawyers, CL ;
Arber, DA ;
Slovak, ML ;
Forman, SJ .
BLOOD, 2003, 101 (12) :4701-4707
[2]   To the editor: Discontinuation of imatinib therapy after achieving a molecular response [J].
Cortes, J ;
O'Brien, S ;
Kantarjian, H .
BLOOD, 2004, 104 (07) :2204-2205
[3]   Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].
Druker, Brian J. ;
Guilhot, Francois ;
O'Brien, Stephen G. ;
Gathmann, Insa ;
Kantarjian, Hagop ;
Gattermann, Norbert ;
Deininger, Michael W. N. ;
Silver, Richard T. ;
Goldman, John M. ;
Stone, Richard M. ;
Cervantes, Francisco ;
Hochhaus, Andreas ;
Powell, Bayard L. ;
Gabrilove, Janice L. ;
Rousselot, Philippe ;
Reiffers, Josy ;
Cornelissen, Jan J. ;
Hughes, Timothy ;
Agis, Hermine ;
Fischer, Thomas ;
Verhoef, Gregor ;
Shepherd, John ;
Saglio, Giuseppe ;
Gratwohl, Alois ;
Nielsen, Johan L. ;
Radich, Jerald P. ;
Simonsson, Bengt ;
Taylor, Kerry ;
Baccarani, Michele ;
So, Charlene ;
Letvak, Laurie ;
Larson, Richard A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417
[4]   Punish the parent not the progeny [J].
Elrick, LJ ;
Jorgensen, HG ;
Mountford, JC ;
Holyoake, TL .
BLOOD, 2005, 105 (05) :1862-1866
[5]   Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? [J].
Goldman, J ;
Gordon, M .
LEUKEMIA & LYMPHOMA, 2006, 47 (01) :1-7
[6]   Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia [J].
Hughes, TP ;
Kaeda, J ;
Branford, S ;
Rudzki, Z ;
Hochhaus, A ;
Hensley, ML ;
Gathmann, I ;
Bolton, AE ;
van Hoomissen, IC ;
Goldman, JM ;
Radich, JP ;
Taylor, K ;
Durrant, S ;
Schwarer, A ;
Joske, D ;
Seymour, J ;
Grigg, A ;
Ma, D ;
Arthur, C ;
Bradstock, K ;
Joshua, D ;
Lechner, K ;
Verhoef, G ;
Louwagie, A ;
Martiat, P ;
Straetmans, N ;
Bosly, A ;
Shepherd, J ;
Shustik, C ;
Lipton, J ;
Kovacs, DM ;
Turner, AR ;
Nielsen, JL ;
Birgens, H ;
Bjerrum, OW ;
Guilhot, F ;
Reiffers, J ;
Rousselot, P ;
Facon, T ;
Harousseau, JL ;
Tulliez, M ;
Guerci, A ;
Blaise, D ;
Maloisel, F ;
Michallet, M ;
Fischer, T ;
Hossfeld, D ;
Mertelsmann, R ;
Andreesen, R ;
Nerl, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1423-1432
[7]   Molecular response to imatinib in late chronic-phase chronic myeloid leukemia [J].
Rosti, G ;
Martinelli, G ;
Bassi, S ;
Amabile, M ;
Trabacchi, E ;
Giannini, B ;
Cilloni, D ;
Izzo, B ;
De Vivo, A ;
Testoni, N ;
Cambrin, GR ;
Bonifazi, F ;
Soverini, S ;
Luatti, S ;
Gottardi, E ;
Alberti, D ;
Pane, F ;
Salvatore, F ;
Saglio, G ;
Baccarani, M .
BLOOD, 2004, 103 (06) :2284-2290
[8]   Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years [J].
Rousselot, Philippe ;
Huguet, Francoise ;
Rea, Delphine ;
Legros, Laurence ;
Cayuela, Jean Michel ;
Maarek, Odile ;
Blanchet, Odile ;
Marit, Gerald ;
Gluckman, Eliane ;
Reiffers, Josy ;
Gardembas, Martine ;
Mahon, Francois-Xavier .
BLOOD, 2007, 109 (01) :58-60